<p>Indian pharma major Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research &amp; Development Corp, on Wednesday announced launch of nasal spray to treat adult Covid-19 patients.</p>.<p>According to Glenmark, the nitric oxide nasal spray (NONS) will be sold under the brand FabiSpray in India for the treatment of adult patients with Covid-19 who have high risk of progression of the disease.</p>.<p>Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.</p>.<p>The nasal spray is designed to kill the coronavirus in the upper airways and when it is sprayed over nasal mucosa, it (nasal spray) acts as a physical and chemical barrier against the virus, preventing it (virus) from incubating and spreading to the lungs.</p>.<p>In July 2021, Glenmark entered into an exclusive long term strategic partnership with Canadian biotech firm SaNOtize, to manufacture, market and distribute its breakthrough NONS for Covid-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.</p>.<p><strong>Check out latest DH videos here</strong></p>
<p>Indian pharma major Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research &amp; Development Corp, on Wednesday announced launch of nasal spray to treat adult Covid-19 patients.</p>.<p>According to Glenmark, the nitric oxide nasal spray (NONS) will be sold under the brand FabiSpray in India for the treatment of adult patients with Covid-19 who have high risk of progression of the disease.</p>.<p>Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.</p>.<p>The nasal spray is designed to kill the coronavirus in the upper airways and when it is sprayed over nasal mucosa, it (nasal spray) acts as a physical and chemical barrier against the virus, preventing it (virus) from incubating and spreading to the lungs.</p>.<p>In July 2021, Glenmark entered into an exclusive long term strategic partnership with Canadian biotech firm SaNOtize, to manufacture, market and distribute its breakthrough NONS for Covid-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.</p>.<p><strong>Check out latest DH videos here</strong></p>